Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Apr 30
Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026 Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026. Annuncio • Mar 19
Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026 Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time. Annuncio • Mar 18
Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025 Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025. Annuncio • Mar 06
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time. Annuncio • Jan 14
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023. Annuncio • Jan 13
Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024 Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024 Board Change • Jun 02
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 18
First quarter 2023 earnings released First quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the United Kingdom. Upcoming Dividend • May 01
Upcoming dividend of €0.80 per share at 1.6% yield Eligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (1.8%). Board Change • Apr 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 11
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 19
Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021) Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Personal Products industry in the United Kingdom. Board Change • Feb 18
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Dec 08
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Dec 07
Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri. Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract to acquire Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. As of year ended 2021, Akern s.r.l. reported revenue of €4.2 million, EBITDA of €1.2 million and net income of €0.58 million. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. As of July 26, 2022, Pharmanutra acquired 72.96% stake in Akern from Red Lions.
Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri on December 5, 2022. Board Change • Oct 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 16
Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021) Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom. Board Change • Aug 04
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Jun 16
Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million. Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. Board Change • Jun 15
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • May 17
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 01
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Feb 24
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Feb 15
PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food PharmaNutra S.p.A. announced that the European Union had published a notice in the Official Gazette authorising the marketing of cetylated fatty acids as a Novel Food. The novel food (Lipocet®) is a combination of myristic acid and oleic acid and, to a lesser degree, other cetylated fatty acids, which until now could be used only in Cetilar®-branded products for topical use. Consequently, PharmaNutra's patented cetylated fatty acids will be included in the EU list of authorised novel foods established in implementing regulation (EU) 2017/2470. The inclusion of the CFAs in the list marks the official completion of the registration procedure under which, in July 2021, the European Food Safety Authority (EFSA) formalised its positive opinion on the safety of CFAs. The Novel Food authorisation is a fundamental new strategic asset for the Group, as it will enable new nutritional supplements based on CFAs to be developed and marketed. The authorisation also provides a protection for industrial property, giving PharmaNutra exclusive right of use for five-year of the new ingredient throughout the European Union. Board Change • Dec 21
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
